MaxCyte, Inc. Grant of Options (2308A)

TIDMMXCT TIDMMXCR

RNS Number : 2308A

MaxCyte, Inc.

10 September 2018

MaxCyte, Inc.

("MaxCyte" or the "Company")

Grant of Options

Maryland, USA - 10 September 2018: MaxCyte (LSE: MXCT, MXCR), a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialisation of next-generation, cell-based medicines, announces that on 18 July 2018, a total of 550,300 options of common stock in the Company ("Common Stock") were granted to PDMRs who are directors or officers of the Company ("Option Grants"). Details of the Option Grants are given below:

 
 Option Grants to PDMRs 
 Doerfler, Doug            296,000 
                          -------- 
 Holtz, Ron                134,800 
                          -------- 
 Thompson, J. Stark        23,900 
                          -------- 
 Mandell, Art              23,900 
                          -------- 
 Erck, Stan                23,900 
                          -------- 
 Brooke, Will              23,900 
                          -------- 
 Johnston, John            23,900 
                          -------- 
 Total                     550,300 
                          -------- 
 

Options Grants to PDMRs vest ratably on a monthly basis over 48 months, have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 18 July 2018, of 243 pence.

About MaxCyte

MaxCyte (LSE: MXCT, MXCR) is a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumors where existing CAR-T approaches face

significant challenges.   For more information, visit http://www.maxcyte.com/ 

###

 
   MaxCyte Inc. 
    Doug Doerfler, Chief Executive Officer 
     Ron Holtz, Chief Financial Officer       [phone] 
 
     Nominated Adviser and Broker 
     Panmure Gordon 
    Emma Earl, Freddy Crossley (Corporate 
     Finance) 
     James Stearns (Corporate Broking)        [phone] 
 
     Financial PR Adviser 
     Consilium Strategic Communications 
    Mary-Jane Elliott                         [phone] 
     Chris Welsh                               [e-mail] 
     Lindsey Neville 
 
 
  1   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Names                        Doerfler, Doug 
                                    Holtz, Ron 
                                    Thompson, J. Stark 
                                    Mandell, Art 
                                    Erck, Stan 
                                    Brooke, Will 
                                    Johnston, John 
     ---------------------------  --------------------------------------------- 
 2    Reason for the notification 
     -------------------------------------------------------------------------- 
 a)   Position/status              Doerfler, Doug - CEO and Director 
                                    Holtz, Ron - CFO and Director 
                                    Thompson, J. Stark - Non-executive Chairman 
                                    Mandell, Art - Non-executive Director 
                                    Erck, Stan - Non-executive Director 
                                    Brooke, Will - Non-executive Director 
                                    Johnston, John - Non-executive Director 
     ---------------------------  --------------------------------------------- 
 b)   Initial notification         Initial Notification 
       /Amendment 
     ---------------------------  --------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     -------------------------------------------------------------------------- 
 a)   Name                         MaxCyte, Inc. 
     ---------------------------  --------------------------------------------- 
 b)   LEI                          54930053YHXULRFCU991 
     ---------------------------  --------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     -------------------------------------------------------------------------- 
 a)   Description of the           Grant of Options over Shares of Common 
       financial instrument,        Stock 
       type of instrument 
     ---------------------------  --------------------------------------------- 
 b)   Identification code          US57777K1060 
     ---------------------------  --------------------------------------------- 
 c)   Nature of the transactions 
                                     Grant of Options to PDMRs 
     ---------------------------  --------------------------------------------- 
 d)   Price(s) and volume(s)       Doerfler, Doug - 296,000 at an exercise 
                                    price of 243pence 
                                    Holtz, Ron - 134,800 at an exercise price 
                                    of 243 pence 
                                    Thompson, J. Stark - 23,900 at an exercise 
                                    price of 243 pence 
                                    Mandell, Art - 23,900 at an exercise price 
                                    of 243 pence 
                                    Erck, Stan - 23,900 at an exercise price 
                                    of 243 pence 
                                    Brooke, Will - 23,900 at an exercise price 
                                    of 243 pence 
                                    Johnston, John - 23,900 at an exercise 
                                    price of 243 pence 
     ---------------------------  --------------------------------------------- 
 d)   Aggregated information        n/a 
       - Aggregated volume 
       - Price 
     ---------------------------  --------------------------------------------- 
 e)   Date of the transactions     18 July 2018 
     ---------------------------  --------------------------------------------- 
 f)   Place of the transaction     Outside a trading venue 
     ---------------------------  --------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHEANNNEEAPEFF

(END) Dow Jones Newswires

September 10, 2018 02:00 ET (06:00 GMT)